Abstract
COVID-19 disease has spread around the world since December 2019. Neurological symptoms are part of its clinical spectrum.
Objective To know the neurological manifestations in patients infected by COVID-19 in Argentina.
Methods Multicenter study conducted in adults, from May 2020 to January 2021, with confirmed COVID-19 and neurological symptoms. Demographic variables, existence of systemic or neurological comorbidities, the form of onset of the infection, alteration in complementary studies and the degree of severity of neurological symptoms were recorded.
Results 817 patients from all over the country were included, 52% male, mean age 38 years, most of them without comorbidities or previous neurological pathology. The first symptom of the infection was neurological in 56.2% of the cases, predominantly headache (69%), then anosmia / ageusia (66%). Myalgias (52%), allodynia / hyperalgesia (18%), and asthenia (6%) were also reported. 3.2% showed diffuse CNS involvement such as encephalopathy or seizures. 1.7% had cerebrovascular complications. Sleep disorders were observed in 3.2%. 6 patients were reported with Guillain Barré (GBS), peripheral neuropathy (3.4%), tongue paresthesia (0.6%), hearing loss (0.4%), plexopathy (0.3%). The severity of neurological symptoms was correlated with age and the existence of comorbidities.
Conclusions Our results, similar to those of other countries, show two types of neurological symptoms associated with COVID-19: some potentially disabling or fatal such as GBS or encephalitis, and others less devastating, but more frequent such as headache or anosmia that demand increasingly long-term care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was evaluated and approved by the research ethics committees of each participating unit: -Instituto Argentino de Investigaciones Neurologicas -Hospital Ramos Mejia -Hospital Durand -Hospital Fernandez _Hospital Privado de la Comunidad _Hospital Universitario CEMIC -Hospital de San Juan -Hospital Italiano de Buenos Aires -Sanatorio Trinidad Mitre -Sanatorio Las Lomas -Instituto Milstein -Hospital Privado de Rosario -Instituto Max Planck -Hospital Enrique Vera Barros -Sanatorio Dr Julio Mendez -Hospital Muniz -Hospital Tornu -Hospital Pinero -Sanatorio Finochietto -Sanatorio del Norte -Centro medico Roca -Hospital Bernardino Rivadavia -Instituto de Neurociencias de Rosario
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
No funding was received for this study.
There are no conflicts of interest.
Data Availability
all data referred in the manuscript are available upon request
